BioSpace News Archive

While MapLight Therapeutics’ oral schizophrenia candidate reached the main endpoint of a Phase 2 trial, analysts say Bristol Myers Squibb’s Cobenfy is likely to hold its market share.

In briefing documents published Monday ahead of an advisory committee meeting for deramiocel, the FDA disagreed with Capricor’s assertion that a Phase 3 trial met its primary outcome measures.

• New division will address the limitations of traditional peptide compounding through 3D printing and AI • PharmaTher plans to connect patients, physicians and qualified pharmacies through an integrated telemedicine platform • Positive PCAC recommendations represent an important potential step toward regulated access to compounded peptides in the United States

Nature Communications Publishes Breakthrough Study Showing How COVID-Era Immune Memory Can Be Redirected to Fight Cancer Celloram, Inc., University Hospitals, and Case Western Reserve University unveil PROTEXI, a novel cancer vaccine platform advancing toward first-in-human clinical trials in sarcoma patients.